Anti-IgE effective in mouse model of persulphate asthma

Omalizumab treatment for patients with occupational asthma has provided benefit for a small number of patients with high molecular weight occupational asthma, but has not helped in 4 workers with low molecular weight agents (isocyanate and acrylate). There is some controversy in the role of IgE antibodies in workers sensitised to persulphates. A new study in mice has shown reduced asthma features in mice dermally sensitised to persulphates and then treated with anti-mouse IgE before nasal challenge with persulphates. A trial in man (or woman) is now warranted.

References

	Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, Mangiapan G, De Blay F, Usefulness of omalizumab in ten patients with severe occupational asthma, Allergy, 2013;68:813-815,

	Munoz X, Cruz MJ, Orriols R, Torres F, Espuga M, Morell F, Validation of specific inhalation challenge for the diagnosis of occupational asthma due to persulphate salts, Occup Environ Med, 2004;61:861-866,

Comments